Skip to main content

Market Overview

Curis Surges 330% On Early Stage Blood Cancer Data

Curis Surges 330% On Early Stage Blood Cancer Data

Curis, Inc. (NASDAQ: CRIS) shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myeloid leukemia and myelodysplastic syndromes. 

What Happened: As of Nov. 23, four AML and three high-risk MDS patients were enrolled in the first two study cohorts of the Phase 1 study that evaluated CA-4948, a small-molecule IRAK4 kinase inhibitor, the company said, citing preliminary data.

No dose-limiting toxicities were observed in the 200mg and 300mg, twice-a-day cohorts, according to Lexington, Massachusetts-based Curis. 

All six evaluable patients showed marrow blast reductions, and two patients experienced a marrow complete response, the company said.

The company also said enrollment has started in the 400mg, twice-a-day arm.

"We are highly encouraged by the breadth of clinical activity with CA-4948 seen with this early data, especially as this study is both monotherapy and in a late line, relapsed/refractory population," CEO James Dentzer said in a statement. 

Related Link: Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace

Why It's Important: Curis shares came under pressure Monday and shed about 24% after it presented at the ASH with not-so-impressive early stage results for the same investigational treatment option in non-Hodgkin's lymphoma.

The sell-side, however, viewed the data as positive.

"We note that the NHL ASH data is in-line with what was previously revealed, so we were surprised to see the stock down over 23% following the announcement. We believe the reported biomarker data bode well for patient selection," H.C. Wainwright analyst Edward White said in a note.

What's Next: Curis said it is comfortable with pace at which its trial partners have been able to enroll patients.

The company said it looks ahead to continuing to advance CA-4948 and reporting additional Phase 1 data in the second half of 2021.

CRIS Price Action: Curis shares were rallying by 364.58% to $6.69 at last check Tuesday. 

Related Link: Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

Latest Ratings for CRIS

Mar 2021B. Riley FBRInitiates Coverage OnBuy
Jan 2021HC Wainwright & Co.MaintainsBuy
Dec 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for CRIS
View the Latest Analyst Ratings


Related Articles (CRIS)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Small Cap Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at